Full Press Release Details
Expanding the Universe of SLC6A19 Substrates: SLC Inhibition Protects Kidney from Nephrotoxic Metabolite Accumulation
The post APRIL 2026 | MAZE THERAPEUTICS appeared first on Maze Therapeutics .
MAZE Positive Sentiment
APRIL 2026 | MAZE THERAPEUTICS
Key Takeaway: Maze Therapeutics is focusing on expanding the understanding of SLC6A19 substrates. Their research indicates that SLC inhibition could play a crucial role in protecting the kidneys from the accumulation of nephrotoxic metabolites. This advancement could have significant implications for kidney health.
Price reaction · baseline $24.27 (2026-06-05 close) · clean, no other MAZE news in the window
day 0 close · peak
-2.8%
Market Sentiment Analysis
POSITIVE FACTORS
- Research on SLC6A19 substrates shows promise.
- SLC inhibition may protect kidneys from damage.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+9%
120-day peak, hindsight
Typical move
1.8%
average across 3 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
MZE829
Phase 2 · Proteinuric Kidney Disease
Frequently Asked Questions
What is the focus of Maze Therapeutics' research?
Maze Therapeutics is focusing on SLC6A19 substrates and their implications.
How does SLC inhibition affect kidney health?
SLC inhibition may protect kidneys from nephrotoxic metabolite accumulation.